A coalition of biotech firms is lobbying to exclude orphan drugs from new federal pilot programs aimed at lowering Medicare drug costs.
Exempting orphan drugs would shrink pilots that already exclude at least some major drugmakers
Adobe
By John WilkersonJuly 21, 2026
John Wilkerson, a Washington correspondent, is the author of D.C. Diagnosis, a twice-weekly newsletter about the politics and policy of health and medicine.
John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07.
Pharma and rare disease advocates press FDA at public hearing on Makary's National Priority Voucher pilot, urging formal…
Plus, GOP voters want a crackdown on health care fraud, and how PBMs are skirting state laws.
FDA's deputy commissioner tells DIA attendees the Trump administration will keep pursuing Makary's user fee priorities as…
President Donald Trump has pushed to lower drug prices for Americans, which are on average nearly three times higher than…
Even as a new drug pricing specter rears its head in President Donald Trump’s “Most Favored Nation” policies, drugmakers continue…
When President Donald Trump rolled out his plan to levy a 100% tariff rate on patented pharmaceutical products and ingredients…
